October 23, 2016
SAN ANTONIO — Study data from the National Pregnancy Registry for Atypical Antipsychotics indicate it is unlikely for second-generation antipsychotics to raise risk of major malformations in pregnancy beyond the 10-fold increase found in the general population, said a study co-author here at the U.S. Psychiatric and Mental Health Congress.
The primary goal of the registry is major malformation frequency in infants exposed to atypical antipsychotics during pregnancy, according to Marlene P. Freeman, MD, of Harvard Medical School and Massachusetts General Hospital. These malformations include heart defects, cleft lip or neural defects. The Registry is based at the Center for Women’s Mental health at Massachusetts General Hospital.